NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $3.57 -0.12 (-3.25%) Closing price 04:00 PM EasternExtended Trading$3.56 -0.01 (-0.34%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.54▼$3.7150-Day Range$3.57▼$4.7952-Week Range$2.40▼$5.47Volume285,667 shsAverage Volume122,007 shsMarket Capitalization$155.26 millionP/E Ratio0.58Dividend Yield7.00%Price TargetN/AConsensus RatingBuy Company Overview Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments. Founded in 2006, Oramed has operations in the United States and Israel. Nadav Kidron serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreORMP MarketRank™: 2.537458379575 of 5 starsOramed Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 411th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingOramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 0.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 0.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 31.98.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.08% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 7.42%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipOramed Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 6.41%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Oramed Pharmaceuticals is 4.06%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Oramed Pharmaceuticals' dividend. News and Social Media2.5 / 5News SentimentN/A News SentimentOramed Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.Percentage Held by Insiders20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORMP Stock News HeadlinesNo Recent Events Reported for Oramed PharmaceuticalsNovember 19 at 4:50 PM | tipranks.comLifeward Reports 18% Third-Quarter AlterG Revenue Growth and Provides Update on ReWalk Commercial TransitionNovember 13, 2026 | quiverquant.comQEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 20 at 1:00 AM | Behind the Markets (Ad)Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMOramed Pharmaceuticals consensus price target increased 12.00% to $7.14September 15, 2026 | msn.comOramed: Q2 Earnings SnapshotAugust 11, 2026 | chron.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comORMP: View inclusion in Russell indexes as positive that could raise awareness in investment communityJune 18, 2026 | msn.comSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.85 at the start of the year. Since then, ORMP stock has increased by 25.3% and is now trading at $3.57. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its earnings results on Thursday, November, 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.43. Who are Oramed Pharmaceuticals' major shareholders? Top institutional shareholders of Oramed Pharmaceuticals include Aquamarine Financial Cayman Ltd (6.38%), BML Capital Management LLC (2.13%), State Street Corp (1.12%) and Ritholtz Wealth Management (0.16%). Insiders that own company stock include Joshua Hexter and Avraham Gabay. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), NIO (NIO), Intel (INTC) and Micron Technology (MU). Company Calendar Last Earnings11/12/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, ORMP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORMP CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees13Year Founded2006Profitability EPS (Trailing Twelve Months)$6.16 Trailing P/E Ratio0.58 Forward P/E RatioN/A P/E GrowthN/ANet Income$64.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-6.97% Return on Assets-6.01% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio4.98 Sales & Book Value Annual Sales$2 million Price / Sales77.63 Cash Flow$0.08 per share Price / Cash Flow42.99 Book Value$7.80 per share Price / Book0.46Miscellaneous Outstanding Shares43,490,000Free Float34,454,000Market Cap$155.26 million OptionableOptionable Beta1.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ORMP) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersSomething Strange Is Happening In MiamiOn December 14, President Trump will host leaders of the world's largest economies at his private Miami resort...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.